- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR
Date/Time: Sunday,
Date/Time:
Abstract Number: 663
Poster Title: “EDP-323, a First-in-Class,
Location: Poster Hall Exhibit
Presenter: Kimberly Mills, PharmD
Further information about the
About
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
View source version on businesswire.com: https://www.businesswire.com/news/home/20230917800366/en/
Media and Investors
617-744-3848
jviera@enanta.com
Source: